Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gain Therapeutics (GANX – Research Report), Humana (HUM – Research Report) and Boston Scientific (BSX – Research Report).
Gain Therapeutics (GANX)
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Gain Therapeutics, with a price target of $10.00. The company’s shares closed last Wednesday at $3.87.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gain Therapeutics with a $8.75 average price target.
See the top stocks recommended by analysts >>
Humana (HUM)
In a report issued on January 30, David S Macdonald from Truist Financial maintained a Hold rating on Humana, with a price target of $400.00. The company’s shares closed last Wednesday at $378.06.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
Humana has an analyst consensus of Moderate Buy, with a price target consensus of $433.31, which is a 14.0% upside from current levels. In a report issued on January 25, Deutsche Bank also downgraded the stock to Hold with a $359.00 price target.
Boston Scientific (BSX)
In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Boston Scientific, with a price target of $72.00. The company’s shares closed last Wednesday at $63.26, close to its 52-week high of $64.49.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $68.22, implying a 6.6% upside from current levels. In a report issued on January 16, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GANX:
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
- Gain Therapeutics files to sell 744,026 shares of common stock for holders
- Gain Therapeutics price target lowered to $9 from $10 at H.C. Wainwright
- Gain Therapeutics announces preclinical data on class of allosteric regulators
